Review ArticlesMolecular Testing for Diagnostics, Prognostication, and Treatment Stratification in CancersHeneidi, Saleh MD; Golden, Jeffrey A. MD; Vail, Eric MD Author Information From the Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA. Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Jeffrey A. Golden, MD, Department of Pathology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, NT2009, Los Angeles, CA 90048. E-mail: [email protected]; Eric Vail, MD, Department of Pathology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, NT2009, Los Angeles, CA 90048. E-mail: [email protected]. The Cancer Journal 29(1):p 3-8, 1/2 2023. | DOI: 10.1097/PPO.0000000000000643 Buy Metrics Abstract Precision cancer care, for essentially all cancer types, now requires molecular diagnostics to assess mutations, chromosomal alterations, and gene expression to personalize treatments for individual patients. Advances in the diagnostics and treatment options have moved the field forward from fundamental discoveries beginning in the 1960s to the development of many targeted therapies that can be as specific as targeting a single-base-pair mutation. Herein is a brief historical perspective on cancer precision medicine with current diagnostic, prognostic, and treatment stratification guidance for early- and late-stage cancers. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.